Cancer Antigen 19-9 Active Protein
Cancer Antigen 19-9 (CA 19-9), Human
Purity
Highly Purified
Synonyms
Cancer Antigen 19-9; Cancer Antigen 19-9 (CA 19-9); Human; Tumor Marker 19-9; CA 19-9; carbohydrate antigen 19-9; Sialylated Lewis (a) Antigen; Cancer Antigen 19-9 active protein
Specificity
Gastrointestinal, Pancreatic Cancer
Purity/Purification
Highly Purified
Form/Format
Solution in 0.1 M phosphate buffered saline pH 7.4 with 3% sucrose and 0.05% sodium azide
Source
Human Metastatic liver carcinoma
Activity
5,000 KIU/mL (Roche Elecsys EIA)
Preparation and Storage
Ships on Dry Ice.
Store at -20°C
Avoid freeze/thaws
Store at -20°C
Avoid freeze/thaws
Related Product Information for Cancer Antigen 19-9 active protein
MyBioSource the leading producer and supplier of Cancer Antigen 19-9 (CA 19-9) for pancreatic management research and biomarker for manufacturing.
Custom preparations, technical support, bulk quantities and aliquoting available.
Cancer Antigen 19-9 is a tumor marker elevated in blood of patients with carcinoma of the gastro-intestinal tract. Primarily used distinguishing pancreatic cancer from pancreatitis, CA 19-9 is not sufficiently specific for use as a cancer screening test. The specificity for pancreatic cancer increases with increasing levels, high levels showing a specificity of >97% for tumor presence. CA 19-9 can be elevated in many types of gastrointestinal cancer, such as colorectal cancer, esophageal cancer and hepatocellular carcinoma.
A group of mucin type glycoprotein Sialosyl Lewis Antigens (SLA), such as CA19-9 and CA19-5, have come to be recognized as circulating cancer associated antigens for gastrointestinal cancer. CA19-9 represents the most important and basic carbohydrate tumor marker. The immunohistologic distribution of CA19-9 in tissues is consistent with the quantitative determination of higher CA19-9 concentrations in cancer than in normal or inflamed tissues. Recently reports indicates that the serum CA19-9 level is frequently elevated in the serum of subjects with various gastrointestinal malignancies, such as pancreatic, colorectal, gastric and hepatic carcinomas. Together with CEA, elevated CA19-9 is suggestive of gallbladder neoplasm in the setting of inflammatory gallbladder disease.
Custom preparations, technical support, bulk quantities and aliquoting available.
Cancer Antigen 19-9 is a tumor marker elevated in blood of patients with carcinoma of the gastro-intestinal tract. Primarily used distinguishing pancreatic cancer from pancreatitis, CA 19-9 is not sufficiently specific for use as a cancer screening test. The specificity for pancreatic cancer increases with increasing levels, high levels showing a specificity of >97% for tumor presence. CA 19-9 can be elevated in many types of gastrointestinal cancer, such as colorectal cancer, esophageal cancer and hepatocellular carcinoma.
A group of mucin type glycoprotein Sialosyl Lewis Antigens (SLA), such as CA19-9 and CA19-5, have come to be recognized as circulating cancer associated antigens for gastrointestinal cancer. CA19-9 represents the most important and basic carbohydrate tumor marker. The immunohistologic distribution of CA19-9 in tissues is consistent with the quantitative determination of higher CA19-9 concentrations in cancer than in normal or inflamed tissues. Recently reports indicates that the serum CA19-9 level is frequently elevated in the serum of subjects with various gastrointestinal malignancies, such as pancreatic, colorectal, gastric and hepatic carcinomas. Together with CEA, elevated CA19-9 is suggestive of gallbladder neoplasm in the setting of inflammatory gallbladder disease.
Product Categories/Family for Cancer Antigen 19-9 active protein
